FDA Brief

Warning letters Biologics

FDA warning letter to

Sperm Bank, Inc. dba Fertility Center of California

High riskIssued Feb 14, 2025Posted Feb 25, 2025Center for Biologics Evaluation and Research (CBER)

FDA warned Sperm Bank, Inc. dba Fertility Center of California over donor semen released without required infectious-disease testing and screening.

What happened

FDA inspected the firm from June 7, 2024 and June 12, 2024. FDA found repeat anonymous semen donors were not tested for West Nile Virus with a licensed nucleic acid test at the first donation in the June 1–October 31 period, donor screening was incomplete, and test specimens were not collected at the time of recovery or within seven days. The letter also says the firm's procedures did not require WNV NAT and that its response to the inspection observations was inadequate.

What FDA found

  1. Repeat anonymous semen donors were not tested for West Nile Virus with a licensed nucleic acid test at the first donation recovered during June 1 through October 31.

    21 CFR 1271.85(a)
  2. Semen from repeat donors was released from quarantine without a complete donor screening procedure within the previous six months.

    21 CFR 1271.75
  3. Donor specimens for communicable disease testing were not collected at recovery or within seven days before or after recovery.

    21 CFR 1271.80(b)
  4. The firm's procedures did not require WNV NAT as an infectious-disease test.

    21 CFR 1271.47(a)

What FDA wants

FDA asks the firm to respond in writing within 15 working days with specific corrective actions, documentation, and steps to prevent recurrence, and to keep affected HCT/Ps in quarantine unless FDA grants an exemption or alternative.

Who should pay attention

  • fertility clinics that use donor semen
  • sperm banks and tissue establishments
  • recipients of donor sperm and their clinicians

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Central Coast Multispecialty Medical Group, Inc.

    FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

    High risk
  2. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk
  3. Louisville Reproductive Center

    Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.

    High risk
  4. Green Valley Fertility Partners

    FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.

    High risk